Parabilis Medicines has entered a strategic collaboration with Regeneron Pharmaceuticals to develop therapeutic candidates using Parabilis’s Helicon™ peptide platform, focusing on Antibody-Helicon™ Conjugates (AHCs). Under the agreement, Parabilis will receive $125 million, including a $50 million upfront payment, with the potential for up to $2.2 billion in milestone payments. The collaboration aims to explore the use of Helicons to target challenging “undruggable” proteins and improve cancer treatment. Regeneron will handle the development and commercialization of the therapies resulting from this partnership.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biospace.com/press-releases/parabilis-medicines-announces-strategic-collaboration-with-regeneron-pharmaceuticals-to-advance-novel-antibody-helicon-conjugates-across-multiple-therapeutic-areas
